0000000000793700

AUTHOR

Peter G. Linde

showing 1 related works from this author

Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.

2018

7018Background: Luspatercept (ACE-536) is a TGF-β family ligand trap promoting late-stage erythroid (E) differentiation and increases in hemoglobin. Endpoints of the ongoing, phase 2, open-label st...

Cancer ResearchOncologybusiness.industryPhase (matter)Myelodysplastic syndromesLuspaterceptCancer researchMedicineHemoglobinbusinessLigand (biochemistry)medicine.diseaseLower riskJournal of Clinical Oncology
researchProduct